Adam Leestma
Family · Demotte, INNPI 1891230140
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 313 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,791, 2.4 times the $732 reported in 2021. Among family clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 313 payments — averaging $17.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$856
- Lilly USA, LLC$367
- Bayer$342
- Boehringer Ingelheim$338
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$276
- plus $2K from 20 others
What the payments were for
- Food & beverage$5,458100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 78 | $1,090 |
| AstraZeneca | 45 | $856 |
| Lilly USA, LLC | 17 | $367 |
| Bayer | 20 | $342 |
| Boehringer Ingelheim | 19 | $338 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $276 |
| Novo Nordisk | 16 | $247 |
| Pfizer | 14 | $226 |
| Phathom Pharmaceuticals, Inc. | 7 | $225 |
| Otsuka America Pharmaceutical, Inc. | 11 | $200 |
| Axsome Therapeutics, Inc. | 6 | $164 |
| Amgen | 9 | $152 |
| GSK | 10 | $130 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $127 |
| Vanda Pharmaceuticals Inc. | 4 | $115 |
| Exact Sciences | 7 | $114 |
| Novartis | 6 | $107 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $75 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $61 |
| Biohaven Pharmaceuticals, Inc. | 3 | $59 |
| Dexcom, Inc. | 3 | $52 |
| Antares Pharma, Inc. | 2 | $46 |
| Astellas Pharma US Inc | 2 | $46 |
| Philips North America LLC | 1 | $16 |
| Johnson & Johnson | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QULIPTA$101
How this compares
$5,458 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 77 | $91,715 |
| JardianceEmpagliflozin | 52 | $72,728 |
| FarxigaDapagliflozin Propanediol | 54 | $69,962 |
| MounjaroTirzepatide | 25 | $28,624 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $28,537 |
| TrulicityDulaglutide | 14 | $28,358 |
| Nurtec OdtRimegepant Sulfate | 15 | $23,016 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 37 | $22,825 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $20,250 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $19,743 |
| EliquisApixaban | 15 | $18,763 |
| JanuviaSitagliptin Phosphate | 11 | $18,016 |
| GlyxambiEmpagliflozin/Linagliptin | 11 | $15,957 |
| TrintellixVortioxetine Hydrobromide | 15 | $7,218 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 131 | $2,234 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $856 | $92,78691 claims |
| Novo NordiskOzempic | $247 | $91,71577 claims |
| Boehringer IngelheimJardiance, Glyxambi | $338 | $88,68563 claims |
| Lilly USA, LLCMounjaro, Trulicity | $367 | $56,98239 claims |
| PfizerNurtec Odt, Eliquis | $226 | $41,77930 claims |
| GSKTrelegy Ellipta | $130 | $28,53726 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $75 | $7,21815 claims |
| AbbVieSynthroid | $1,090 | $1,82120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,392 family providers in Indiana.
Other family in Demotte
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.